Acta Scientific Pharmaceutical Sciences (ASPS)(ISSN: 2581-5423)

Research Article Volume 6 Issue 3

Simultaneous Estimation of Ceritinib and Lenvatinib Using RP-HPLC Method

Dasari Vasavi Devi* and Shaik Umme Salma

Pharmaceutical Analysis, P. Ramireddy Memorial College of Pharmacy, India

*Corresponding Author: Dasari Vasavi Devi, Pharmaceutical Analysis, P. Ramireddy Memorial College of Pharmacy, India.

Received: January 06, 2022; Published: March 02, 2022

Abstract

High performance liquid chromatography is at present one of the most sophisticated tool of the analysis. The assessment of Ceritinib and Lenvatinib was run by RP-HPLC. The Methanol: Phosphate buffer in the ratio of 70: 30% v/v which consists of buffer pH 3.0 was used as a mobile phase. The stationary phase used in the present analysis was Inertsil ODS column (4.6 x 150 mm, 5 µm). The PDA detector with detecting wavelength of 260 nm was used for identification of the separated drugs. The constant flow rate with 1ml/min was employed for efficient separation of the components. The linearity range of Ceritinib and Lenvatinib was found to be from 100 - 500 ppm of Ceritinib and 1 - 5 ppm of Lenvatinib. Linear regression coefficient was not more than 0.999. The values of% RSD are less than 1% indicating precision of the method. The percentage recovery differs from 98 - 102% of Ceritinib and lenvatinib. It surmised that the method was viewed as simple, linear, precise and accurate as per ICH requirements. The method was viewed as having reasonable application in routine lab analysis with high level of accuracy and precision.

Keywords: Inertsil ODS; Ceritinib and Lenvatinib; RP-HPLC

References

  1. Blass B. “Basic Principles of Drug Discovery and Development”. 1st edition. Amsterdam: Academic Press (2015).
  2. Drug Analysis by Shaza W. Shantier Submitted (2019).
  3. Pharma analysis, Pharmatutor infopedia (2013).
  4. Julie M Janssen., et al. “Development and validation of a liquid chromatography-tandem mass spectrometry assay for nine oral anticancer drugs in human plasma”. Journal of Pharmaceutical and Biomedical Analysis10 (2019): 561-566.
  5. MSV Sakuntala., et al. “Development and validation of HPLC method for determination of Ceritinib in Rabbit Plasma using PDA Detector”. International Journal of Pharmaceutical Sciences and Research7 (2018): 2897-2904.
  6. Jahnavi Bandla S Ganapaty. “New Stability-Indicating Ultra Performance Liquid Chromatography Method Development and Validation of Lenvatinib Mesylate in Bulk Drug and Pharmaceutical Dosage Forms”. Asian Journal of Pharmaceutical and Clinical Research 9 (2018): 140-143.
  7. Fatemeh Aghai., et al. “Development and validation of a sensitive liquid chromatography tandem mass spectrometry assay for the simultaneous determination of ten kinase inhibitors in human serum and plasma”. Analytical and Bioanalytical Chemistry 413 (2021): 599-612.
  8. Vaibhav Suresh Adhao., et al. “Development and validation of Stability Indicating RP-HPLC method for determination of Ceritinib”. Indonesian Journal of Pharmacy4 (2017): 241-248.
  9. Dr K Nageswara Rao., et al. “Novel RP-HPLC Method Development and Validation of Dasatinib and Lenvatinib in Bulk and Pharmaceutical Dosage Forms”. International Journal of Current Trends in Pharmaceutical Research2 (2019): 50-56.
  10. Y Prashanthi., et al. “Method Development and Validation of Lenvatinib Drug by RP-HPLC in Pharmaceutical Drug Dosage Form”. Indo American Journal of Pharmaceutical Sciences10 (2016): 1078-1085.
  11. ICH Harmonised Tripartite Guideline, Validation of analytical procedures: Text and methodology, Q2 (R1), International Conference on Harmonization, Geneva (2005): 1-13.

Citation

Citation: Dasari Vasavi Devi and Shaik Umme Salma. “Simultaneous Estimation of Ceritinib and Lenvatinib Using RP-HPLC Method". Acta Scientific Pharmaceutical Sciences 6.3 (2022): 02-07.

Copyright

Copyright: © 2022 Dasari Vasavi Devi and Shaik Umme Salma. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Metrics

Acceptance rate32%
Acceptance to publication20-30 days

Indexed In




News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is July 10, 2022.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US